Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neuropathic Pain Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMEM37 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM37 Recombinant Protein (Extracellular Loop) High purity (>95%), Endotoxin Controlled (<1EU/ug). Sequence Verified. HEK293 Expressed. |
View TMEM37 Products |
| Gene Delivery | TMEM37 Promise-ORF / Lentivirus Full-length ORF for stable cell line development. Preserves native multi-pass conformation. |
View TMEM37 Products |
| Benchmark Ab | Anti-TMEM37 Recombinant Antibody Recombinant positive control for validation assays. |
View TMEM37 Products |
| Validator | TMEM37 siRNA Set For target knockdown verification in functional assays. |
View TMEM37 Products |
| Related Target A | CACNA1B Voltage-gated calcium channel subunit alpha-1B; primary functional partner regulated by TMEM37 in pain pathways. |
View CACNA1B Products |
| Related Target B | CACNA1C Voltage-gated calcium channel subunit alpha-1C; co-expressed subunit modulated in excitable tissues. |
View CACNA1C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane conformation preservation | Lentivirus-driven stable cell line generation for cell-based calcium flux and patch-clamp assays |
| Selectivity against CACNG family homologs | Homolog panel screening using sequence-verified recombinant proteins |
| Lack of clinical benchmarks | Recombinant positive control antibodies included |
| False positives in binding assays | Validated siRNA included for specificity and knockdown checks |
Live TMEM37 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The exploration of TMEM37 (transmembrane protein 37, also known as voltage-dependent calcium channel gamma-like subunit) is gaining traction in both neuropharmacology and oncology. Originally characterized as a regulatory subunit modulating voltage-gated calcium channels, recent studies highlight its aberrant expression in solid tumors, particularly gastric and hepatocellular carcinomas. The race for TMEM37 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted small molecule modulators and antibody-drug conjugates (ADCs) targeting its extracellular domains. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific calcium channel complexes and pain-associated signaling pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Oncology Biotechs | Gastric Cancer, HCC | Internalization Assay (Need high-purity extracellular loop proteins and stable cell lines) |
| Small Molecule Modulator | Neuro-therapeutics Specialists | Neuropathic Pain | Calcium Flux & Patch Clamp (Need Lentivirus for high-expression stable cell lines) |
| Monoclonal Antibody | Academic & Clinical Consortia | Refractory Solid Tumors | Selectivity Assay (Need Mutant vs WT Proteins to avoid cardiac channel cross-reactivity) |